• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Jubilant Therapeutics Appoints Chief Scientific Officer

    Iontas and Fair Journey Biologics Partner with Quell Therapeutics

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Vetter Establishes Office in China

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Alcami

    Cytovance Biologics

    Almac Group

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Cytovance Biologics

    Reed-Lane

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biopharma Contract Fill-and-Finish Market Trends

    Biopharmaceuticals continue to fuel growth in the pharmaceutical industry.

    Biopharma Contract Fill-and-Finish Market Trends
    Related CONTENT
    • Asymchem
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • Regis Custom Pharma
    Cindy Liu and William Downey, HighTech Business Decisions03.06.19
    The market for biopharmaceuticals continues to expand worldwide, and they have been the primary growth driver for the pharmaceutical industry. Biopharmaceuticals will continue to provide significant growth for the pharmaceutical market over the next five years. Biopharmaceutical contract fill-and-finish has expanded in recent years as more biopharmaceuticals enter the market. Pharmaceutical and biotechnology companies look to contract manufacturing organizations (CMOs) as a way to meet their fill-and-finish needs and reduce risk. This article reviews selected market trends, the use of multi-molecule agreements, and underserved market segments.

    Background
    The information presented in this article draws from HighTech Business Decisions’ latest report, “Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018.” The findings in this report come from primary research through interviews and written surveys from senior-level executives and scientists at pharmaceutical and biotechnology companies and fill-and-finish contract manufacturing organizations. For purposes of our article, we define biopharmaceuticals as complex molecules created through the genetic manipulation of living cells or organisms used for therapeutics or vaccines. We define fill-and-finish CMOs as contract manufacturing organizations that provide drug product manufacturing services under a fee-for-service contract. Manufacturing services include formulation, fill, packaging and labeling, lyophilization, and other services for the final production of the drug product. 

    Fill-and-finish services outsourced
    Contract fill-and-finish services remain one of the most outsourced services today. Almost all pharmaceutical and biotechnology companies outsource at least a portion of their fill-and-finish needs. A virtual start-up company uses a CMO because it lacks both capacity and the means to build capacity. Large companies with in-house fill-and-finish capacity outsource at least some of its fill-and-finish needs to lower supply chain risks. The reasons to use a CMO’s capacity include unexpected demand, second source policies, or better matching scale with need. Companies with in-house capacity will also use a CMO when it lacks the ability to produce novel products or formats. Specialized capabilities such as lyophilization, filling prefilled syringes and cartridges, or novel therapeutics may require specialized manufacturing that may be more cost-effective to outsource. For those companies with in-house aseptic fill-and-finish capacity, they outsource on average 39% of their fill-and-finish needs. 

    Most companies outsource some portion of aseptic filling (96% of respondents), and analytical testing (92%), see Figure A. On the other hand, regulatory related services and IND consultancy mostly remain in-house. This may be because many companies a) have internal regulatory departments, b) use consultants who specialize in this area, or c) use CMOs that do not offer this service. Over the next three years, all companies will outsource some portion of their fill needs. One service area that will significantly increase is lyophilization. From our study, we see the share of companies that outsource lyophilization increase from 44% to 72%. Conversely, regulatory assistance share increases modestly from 36% to 44%. Most companies will continue to keep regulatory work in-house. From our analysis, the two largest fill-and-finish market segments are filling, which accounts for 59% of total market, and lyophilization, which accounts for 24% of the total market.




    Price change for fill-and-finish services in last two years
    Given the continued strong outsourcing trend in fill-and-finish services, it is worthwhile to explore how prices have changed from both user and CMOs’ view. In general, our study finds that more user respondents saw higher prices than CMO respondents (see Figure B). Most respondents report price increases between 3% and 10%, but some have reported increases greater than 10%, especially in the area of viral products. Some users credit the price increase to new rules aimed to improve sterility. This resulted in CMOs overhauling their fill areas and creating aseptic environment by installing isolators and RABS systems. CMOs on the other hand reported more stable pricing. A few CMOs commented that their pricing is supply and demand driven where a unique capability and lack of competition in certain segment commands slightly higher prices.




    Below are selected comments from our study’s respondents regarding their observations of price changes in the last two years:

    • “We have had a 30% increase in the past five to six years. We’ve seen prices go up a lot. There are new regulations. Most CMOs had to revamp their filling area, installing grade A clean spaces between the filling machine and lyophilizer.”  —Pharma/Biotechnology Respondent

    • “For viral products, we have experienced an increase of 40% to 50%.”  —Pharma/Biotechnology Respondent

    • “Price increases have been more than 10% for certain capabilities, e.g., prefilled syringes, in part because there are fewer suppliers. Price increases have also been higher in certain regions where there are fewer options and where government regulations say products to be sold there must be manufactured there. It’s a matter of supply and demand.” —CMO Respondent

    Effect of multi-molecule agreement on pricing
    To stabilize prices, companies with multiple products have multi-molecule agreements with their CMOs. The most significant value-add of a multi-molecule or master service agreement according to the CMO respondents is price discounts. With multi-molecule agreements, CMOs can plan for larger quantity purchases and share those savings with their clients.

    Besides lower prices, clients with multi-molecule agreements also benefit from flexibility of reserving capacity across the CMO’s network. Thus, reserved capacity is not tied to a specific molecule; when forecasts change, the client can rebalance their needs based on their overall portfolio demand. This reduces costs and cancellation fees.

    An intangible but valuable advantage of a multi-molecule agreement is the seamless management of multiple projects by the CMO. CMOs use the same project manager who oversees the client’s entire outsourced portfolio. This continuity leads to faster contract facilitation from additional work orders. It also promotes good communication—always a challenge in client management.

    Although each CMO agreement differs, these agreements offer benefits to both parties and help keep long-term relationships. However, not all CMOs offer these agreements; about half the CMOs (55%) offer multi-molecule or master service agreements. 

    The following are selected comments from CMOs on their offering of the multi-molecule or master service agreements and the benefits they provide:

    • “For multi-molecule agreements, we give our customers a price break. They are also assigned to the same project manager for continuity and more seamless management of multiple projects. Ordering vials and syringes in larger quantities can also provide the price break.” —CMO Respondent

    • “Our pricing structure has three variables: price, number of units, and terms. The fourth variable would be the number of molecules. Our project management costs won’t change but for larger volumes and long-term relationships there is an advantage for us. We are open to master agreements with the terms that are favorable for both parties. However, sometimes this leads to more misunderstandings and demands which can be more difficult.”  —CMO Respondent

    • “It’s an important part of our growing business. We can support companies with multiple products in development across multiple sites. We have an enterprise capacity model. Rather than just pricing per unit or straight fee-for-service, customers can reserve capacity, e.g., 50 batches/years across our entire network. It’s meant to give more flexibility to our customers.” —CMO Respondent

    Underserved market segments
    Eighty-nine percent of the companies in our study have difficulty outsourcing all their production needs. Services and production for ADCs, live viruses, cytotoxics with slow-release formulations, and small-batch runs are all areas with limited choices. Technologies like ADCs and cell therapies need specialized manufacturing. The respondents report a limited number of CMOs and a scarcity of good-quality capacity with state-of-the-art equipment to support their production needs. In particular, companies working with live virus report supply shortages and significant price increases. These are potential growth opportunities for fill-and-finish CMOs.

    The respondents also note shortages of ancillary services such as analytical testing, release and stability testing. Often, third-party CROs perform these services because fill-and-finish CMOs do not provide the service. CMOs that provide analytical services help simplify their clients’ supply chain and differentiate themselves from their competitors.

    Finally, while not technically a market segment, CMOs who have continued to invest in equipment and process technologies are at a competitive advantage. A few respondents told us about their concerns over CMOs with outdated filling equipment or semi-automated systems. Newer technology equipment streamlines the manufacturing process and increases efficiency while reducing risks. Fully automated systems and disposable setup provide flexibility and reduce cross-contamination. This allows more CMOs to take on novel therapeutics such as live virus products and helps with capacity planning.

    Below are selected comments from biopharmaceutical respondents regarding their view of underserved areas by the fill-and-finish CMOs:

    • “ADC manufacturing is underserved. We would like to see more CMOs that can offer this specialized manufacturing. ADC manufacturing is challenging. ADCs require extra monitoring, cleaning and validation. Changeover for ADC products is not simple, compared to mAbs. Disposable facilities are attractive for this reason. They save time and money on cleaning and validation.” 
    —Pharma/Biotechnology Respondent

    • “The viral space is underserved, starting from drug substance and going forward. There are not many CMOs willing to work with viruses so they can charge whatever price they want. Even when they are willing to work with viruses, most specialize in adenovirus and they don’t want to add another virus to the mix. With a small number of suppliers, the price goes up. The virus space is overheated.”  —Pharma/Biotechnology Respondent

    • “Live products are difficult to get done. Because the product is unstable, we prefer to do the fermentation, fill and lyophilization at the same site. The knowledge supporting lyophilization activities was surprisingly weak. Another unfilled need is that no one offers large lyophilization capacity.”  —Pharma/Biotechnology Respondent

    • “Personalized medicine is underserved. There is a big trend for drug candidates designed specifically for one person, which will mean there are a large number of small batches. From a timing perspective, manufacturing will be unpredictable, and the cost and scale of very small batches will be difficult. The current CMO model of manufacturing is not compatible with this type of manufacturing.”  —Pharma/Biotechnology Respondent

    • “Fill-and-finish CMOs have development capabilities but often no analytical support. We generally have to find another CMO for analytical testing. If fill-and-finish CMOs offered these services it would add flexibility and would be a big advantage to us.” —Pharma/Biotechnology Respondent

    • “In addition to drug product manufacturing, we also outsource formulation development, analytical development, analytical testing and analytical qualification. It would be nice to have a CMO that provides multiple services but I would choose go to the CMO that provides the best match for formulation or the best match for analytical activities.”  —Pharma/Biotechnology Respondent

    • “They’re slow to move to newer technologies. Some don’t have the capital to make the investments, but it’s not just a money issue because it’s a problem with both small and large companies. Fill-and-finish CMOs are way behind on filling equipment. They need to streamline to make more product faster and with less risk. The higher throughput would benefit them and me.” 
    —Pharma/Biotechnology Respondent

    • “For clinical projects, I know of very few adaptive, fully flexible CMOs—where the set-up is all disposable and the CMO can easily move from viral projects to non-viral then back again. I know new requirements for sterility and isolators limit flexibility. Few [CMOs] have this flexibility. They are all product and dosage form specialists.”  —Pharma/Biotechnology Respondent

    • “There are not that many top tier fill-and-finish CMOs in the U.S., so there isn’t enough high-quality capacity. We need existing high quality CMOs to expand their capacity and for new ones to come online. But no one wants to spend the money. Some existing high quality CMOs only do early phase. It would help if they invested in commercial as well. That’s more likely to happen than investments to bring new fill-and-finish CMOs online.”  —Pharma/Biotechnology Respondent

    Closing
    The pharmaceutical and biotechnology companies’ production strategy drives the market for contract fill-and-finish capacity and capability. Filling and lyophilization services continue to be significant market segments. Overall prices have increased modestly, and this trend will continue with expanded regulations and greater CMO investments in capabilities. Multi-molecule agreement provides benefits for both clients and CMOs. New technologies and capacity to meet the needs for novel drug products are underserved segments that will fuel industry growth. 


    Cindy LIu is managing director and William Downey is president of HighTech Business Decisions, a market research and consulting company that has been publishing reports on the biopharmaceutical contract manufacturing market since 1997. For more information, visit www.hightechdecisions.com or call (408) 978-1035.
    Related Searches
    • capacity
    • labeling
    • Development
    • Testing
    Suggested For You
    Asymchem Asymchem
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Regis Custom Pharma Regis Custom Pharma
    Softweb Solutions Softweb Solutions
    Dexios Dexios
    Vetio Animal Health Vetio Animal Health
    Adare Pharma Solutions Adare Pharma Solutions
    Abpro and NJCTTQ Ink $4B Development Deal Abpro and NJCTTQ Ink $4B Development Deal
    Onconova Appoints CEO Onconova Appoints CEO
    Averica Announces New Leadership Team Averica Announces New Leadership Team
    Novartis Makes Offer for French CDMO Novartis Makes Offer for French CDMO
    QPS Expands U.S.-Based Phase I Clinical Trial Services QPS Expands U.S.-Based Phase I Clinical Trial Services
    PSC Biotech PSC Biotech

    Related Features

    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • APIs | Cytotoxics and High Potency Manufacturing
      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • APIs
      Small Molecule API CDMO: A Capital Intensive Business?

      Small Molecule API CDMO: A Capital Intensive Business?

      Exploring small molecule API market trends.
      Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers 03.01.21


    • Serialization
      Serialization: Level 5 Solution

      Serialization: Level 5 Solution

      Why a Level 5 solution is required for small pharma companies to fully harness serialization investment.
      Steve Wood, President & CEO, Covectra 03.01.21

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    Trending
    • Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement For Novavax’ COVID-19 Vaccine
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Pharmaron Acquires Biomanufacturing Site In The UK From AbbVie
    Breaking News
    • Jubilant Therapeutics Appoints Chief Scientific Officer
    • Iontas and Fair Journey Biologics Partner with Quell Therapeutics
    • Vetter Establishes Office in China
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Diets High In Fructose Could Cause Immune System Damage
    Nestlé Acquires Premium Water Brand Essentia
    Kaneka Probiotics Announces Launch of L. plantarum DR7
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs First OTC Home Molecular COVID-19 Test
    FDA Approves Second Sight's Argus 2s Retinal Prosthesis
    Cross Border Venture Financing Rose in Final Quarter of 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sharp Appoints EU Qualified Person
    Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine
    Metrics Contract Services Completes Russian Regulatory Inspection
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    It's International Women's Day—But What Does That Mean?
    e.l.f. Cosmetics and Chipotle Collaborate on Burrito-Inspired Makeup Collection
    Weekly Recap: Sephora Expansion, Ulta Partners with Loop, International Women’s Day & More
    Happi

    Latest Breaking News From Happi

    Cococare Appoints First Woman President
    Ross Highlights Triple Shaft Mixers
    Arm & Hammer Unveils Foot Wipes
    Ink World

    Latest Breaking News From Ink World

    Capital Printing Invests in 2nd Komori Press
    Arna Marketing Adds Canon’s ProStream, VarioPRINT iX Production Inkjet Presses
    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Xeikon details upcoming Xeikon Café TV seminars
    Resource Label Group acquires New England Label
    UV+EB-cured products rated 'easier to recycle'
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Arm & Hammer Launches Foot Wipes
    Kimberly-Clark Names Chief Research and Development Officer
    FPInnovations Develops Biodegradable Mask
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Australia Clears Conformis' iTotal PS Knee Replacement System
    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Wearable Patch Market to Reach $27.8 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login